Statins may protect against hepatocellular carcinoma development in patients infected with hepatitis C virus, but what are the mechanisms?

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4160-4161

  Clément, Sophie ^a   Peyrou, Marion ^b   Foti, Michelangelo ^b   Negro, Francesco ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

CANCER CHEMOTHERAPY; CARCINOGENESIS; CHROMOSOME 10; DISEASE COURSE; DISEASE MARKER; DOSE RESPONSE; DOWN REGULATION; FATTY LIVER; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LETTER; LIPID METABOLISM; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER PROTECTION; MORPHOGENESIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL; TREATMENT FAILURE; VIRAL CLEARANCE; VIREMIA; VIRION; VIRUS LOAD; VIRUS REPLICATION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; FEMALE; LIVER NEOPLASMS; MALE; LIVER TUMOR; NOTE;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; MALE;

EID: 84891724290     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.0354     Document Type: Letter

References (20)

1. Tsan YT, Lee CH, Ho WC, et al: Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 31:1514-1521, 2013
2. Siegel AB: An ounce of prevention is better than a pound of cure: A patient-centered approach to hepatocellular carcinoma. J Clin Oncol 31:1499-1501, 2013
3. El-Serag HB, Johnson ML, Hachem C, et al: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136:1601-1608, 2009
4. Tsan YT, Lee CH, Wang JD, et al: Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 30:623-630, 2012
5. Nielsen SF, Nordestgaard BG, Bojesen SE: Statin use and reduced cancer-related mortality. N Engl J Med 367:1792-1802, 2012
6. Syed GH, Amako Y, Siddiqui A: Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metabolism 21:33-40, 2010
7. Ikeda M, Abe K, Yamada M, et al: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117-125, 2006 (Pubitemid 44049145)
8. Kapadia SB, Chisari FV: Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102:2561-2566, 2005 (Pubitemid 40279416)
9. Peyrou M, Clément S, Maier C, et al: PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. J Hepatol 59:420-426, 2013
10. Rao GA, Pandya PK: Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 140:144-152, 2011
11. Clement S, Peyrou M, Sanchez-Pareja A, et al: Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology 54:38-49, 2011
12. Leslie NR, Foti M: Non-genomic loss of PTEN function in cancer: Not in my genes. Trends Pharmacol Sci 32:131-140, 2011
13. Berger AH, Pandolfi PP: Haplo-insufficiency: A driving force in cancer. J Pathol 223:137-146, 2011
14. Horie Y, Suzuki A, Kataoka E, et al: Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113:1774-1783, 2004 (Pubitemid 39071669)
15. Vinciguerra M, Veyrat-Durebex C, Moukil MA, et al: PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134:268-280, 2008 (Pubitemid 350309315)
16. Rahman MA, Kyriazanos ID, Ono T, et al: Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: Possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer 100:152-157, 2002 (Pubitemid 34666188)
17. Nkontchou G, Ziol M, Aout M, et al: HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 18:516-522, 2011
18. van der Meer AJ, Veldt BJ, Feld JJ, et al: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:2584-2593, 2012
19. Ohata K, Hamasaki K, Toriyama K, et al: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97:3036-3043, 2003 (Pubitemid 36676258)
20. Pekow JR, Bhan AK, Zheng H, et al: Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109:2490-2496, 2007 (Pubitemid 46908652)